On Wednesday, Ranbaxy Laboratories said that it would not be able to introduce a generic variant of a urinary medicine in the US as per schedule, as there has not been a final approval from the regulator yet.

On Wednesday, Ranbaxy Laboratories said that it would not be able to introduce a generic variant of a urinary medicine in the US as per schedule, as there has not been a final approval from the regulator yet.

India'a largest pharmaceutical company Ranbaxy Laboratories Ltd has finally got nod from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) and Quinapril Hydrochloride & Hydrochlotothiazide (Quinapril + HCTZ) Tablets, an ACE inhibitor which is used to treat high blood pressure.

U. S. health officials said the review of any new drug applications from a Ranbaxy Laboratories plant in India has been halted after it was discovered that scientific data was falsified.